- Home
- DRMA vs SANW Comparison
DRMA vs SANW Comparison
Compare DRMA & SANW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- SANW
- Stock Information
- Founded
- DRMA 2014
- SANW 1980
- Country
- DRMA United States
- SANW United States
- Employees
- DRMA N/A
- SANW N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- SANW Farming/Seeds/Milling
- Sector
- DRMA Health Care
- SANW Consumer Staples
- Exchange
- DRMA Nasdaq
- SANW Nasdaq
- Market Cap
- DRMA 4.5M
- SANW 4.6M
- IPO Year
- DRMA 2021
- SANW 2010
- Fundamental
- Price
- DRMA $0.71
- SANW $2.39
- Analyst Decision
- DRMA Strong Buy
- SANW Strong Buy
- Analyst Count
- DRMA 1
- SANW 1
- Target Price
- DRMA $3.00
- SANW $25.00
- AVG Volume (30 Days)
- DRMA 118.5K
- SANW 100.2K
- Earning Date
- DRMA 08-06-2025
- SANW 05-15-2025
- Dividend Yield
- DRMA N/A
- SANW N/A
- EPS Growth
- DRMA N/A
- SANW N/A
- EPS
- DRMA N/A
- SANW N/A
- Revenue
- DRMA N/A
- SANW $54,993,808.00
- Revenue This Year
- DRMA N/A
- SANW N/A
- Revenue Next Year
- DRMA N/A
- SANW $17.19
- P/E Ratio
- DRMA N/A
- SANW N/A
- Revenue Growth
- DRMA N/A
- SANW 6.91
- 52 Week Low
- DRMA $0.57
- SANW $1.99
- 52 Week High
- DRMA $5.00
- SANW $11.60
- Technical
- Relative Strength Index (RSI)
- DRMA 53.74
- SANW 30.12
- Support Level
- DRMA $0.61
- SANW $2.00
- Resistance Level
- DRMA $0.74
- SANW $2.21
- Average True Range (ATR)
- DRMA 0.06
- SANW 0.41
- MACD
- DRMA 0.01
- SANW 0.02
- Stochastic Oscillator
- DRMA 67.43
- SANW 13.07
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About SANW S&W Seed Company (NV)
S&W Seed Co is a multi-crop, middle-market agricultural company. It is engaged in the breeding, production, and sale of alfalfa seed and sorghum seed. It also has a growing commercial market presence in sunflower and maintains an active stevia development program. The company's seed platform develops and supplies germplasm designed to produce higher yields for farmers globally. Its geographical segments include the United States, Australia, Saudi Arabia, Mexico, South Africa, and other countries. Maximum of revenue is earned from USA following Australia second and Mexico third.